Therefore, we recommend routine monitoring of CD4 counts by flow cytometry in patients on long-term use of fingolimod therapy (at least five years), even without lymphopenia, and we believe that clinical and dermatoscopic examination should be performed regularly every six months for the development of skin malignancies. This evidence concerns the gene CD4 and lymphopenia.